These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Thromboxane agonism and antagonism in a mouse sudden death model. Myers A; Penhos J; Ramey E; Ramwell P J Pharmacol Exp Ther; 1983 Feb; 224(2):369-72. PubMed ID: 6822961 [TBL] [Abstract][Full Text] [Related]
3. Blockade of thromboxane and the prevention of eicosanoid-induced sudden death in mice. Darius H; Lefer AM Proc Soc Exp Biol Med; 1985 Nov; 180(2):364-8. PubMed ID: 2996012 [TBL] [Abstract][Full Text] [Related]
4. Assessment of the pyrogenic potency of the thromboxane A2-mimetics, SQ26655 and U46619, and thromboxane B2 by intrapreoptic injection in the cat. Gollman HM; Rudy TA Res Commun Chem Pathol Pharmacol; 1985 Aug; 49(2):305-8. PubMed ID: 3864207 [TBL] [Abstract][Full Text] [Related]
5. Mechanism of the protective action of Bay-u-3405, a new specific thromboxane receptor antagonist, in arachidonate-induced sudden death. Ma XL; Karasawa A; Lefer AM Methods Find Exp Clin Pharmacol; 1991 Mar; 13(2):105-10. PubMed ID: 1906568 [TBL] [Abstract][Full Text] [Related]
6. Role of thromboxanes and prostaglandin endoperoxides in the pathogenesis of eicosanoid induced sudden death. Lefer AM; Burke SE; Smith JB Thromb Res; 1983 Nov; 32(3):311-20. PubMed ID: 6419378 [TBL] [Abstract][Full Text] [Related]
7. Roles of thromboxanes in gastrointestinal physiopathology. Bennett TA Int J Tissue React; 1983; 5(3):237-9. PubMed ID: 6686219 [TBL] [Abstract][Full Text] [Related]
8. Effect of BAY U 3405, a new thromboxane antagonist, on arachidonic acid induced thromboembolism. Seuter F; Perzborn E; Fiedler VB Adv Prostaglandin Thromboxane Leukot Res; 1991; 21A():355-8. PubMed ID: 1825569 [TBL] [Abstract][Full Text] [Related]
9. Arachidonic acid-induced platelet aggregation is mediated by a thromboxane A2/prostaglandin H2 receptor interaction. Parise LV; Venton DL; Le Breton GC J Pharmacol Exp Ther; 1984 Jan; 228(1):240-4. PubMed ID: 6319669 [TBL] [Abstract][Full Text] [Related]
10. Effects of combined thromboxane synthetase inhibition/thromboxane receptor antagonism in two models of sudden cardiac death in the canine: limited role for thromboxane. Kitzen JM; Chi LG; Uprichard AC; Lucchesi BR J Cardiovasc Pharmacol; 1990 Jul; 16(1):68-80. PubMed ID: 1696668 [TBL] [Abstract][Full Text] [Related]
11. Comparison of verapamil and nifedipine in thrombosis models. Myers AK; Forman G; Torres Duarte AP; Penhos J; Ramwell P Proc Soc Exp Biol Med; 1986 Oct; 183(1):86-91. PubMed ID: 3092231 [TBL] [Abstract][Full Text] [Related]
12. Protective effects of a new specific thromboxane antagonist in arachidonate-induced sudden death. Lefer DJ; Mentley RK; Lefer AM Arch Int Pharmacodyn Ther; 1987 May; 287(1):89-95. PubMed ID: 2957969 [TBL] [Abstract][Full Text] [Related]
13. Antiaggregant and antivasospastic properties of the new thromboxane A2 receptor antagonist sodium 4-[[1-[[[(4-chlorophenyl)sulfonyl]amino]methyl]cyclopentyl] methyl]benzeneacetate. Lardy C; Rousselot C; Chavernac G; Depin JC; Guerrier D Arzneimittelforschung; 1994 Nov; 44(11):1196-202. PubMed ID: 7848331 [TBL] [Abstract][Full Text] [Related]
14. Antagonism of thromboxane A2/prostaglandin H2 by 13-azaprostanoic acid prevents platelet deposition to the de-endothelialized rabbit aorta in vivo. Le Breton GC; Lipowski JP; Feinberg H; Venton DL; Ho T; Wu KK J Pharmacol Exp Ther; 1984 Apr; 229(1):80-4. PubMed ID: 6423815 [TBL] [Abstract][Full Text] [Related]
15. Inhibitory effects of the selective thromboxane receptor antagonist BM 13.177 on platelet aggregation, vasoconstriction and sudden death. Patscheke H; Stegmeier K; Müller-Beckmann B; Sponer G; Staiger C; Neugebauer G Biomed Biochim Acta; 1984; 43(8-9):S312-8. PubMed ID: 6097235 [TBL] [Abstract][Full Text] [Related]
16. Protective actions of a new potent thromboxane receptor antagonist in arachidonate induced sudden death. Liao P; Johnson G; Siegfried M; Lefer AM Eicosanoids; 1989; 2(1):33-7. PubMed ID: 2534470 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of prostanoid-mediated platelet aggregation in vivo and in vitro by 3-hydroxymethyl-dibenzo(b,f)thiepin 5,5-dioxide (L-640,035). Chan CC; Nathaniel DJ; Yusko PJ; Hall RA; Ford-Hutchinson AW J Pharmacol Exp Ther; 1984 Apr; 229(1):276-82. PubMed ID: 6423813 [TBL] [Abstract][Full Text] [Related]
18. SIN-1, the main metabolite of molsidomine, inhibits prostaglandin endoperoxide analogue- and arachidonic acid-induced platelet aggregation as well as platelet thromboxane A2 formation. Block HU; Förster W; Heinroth I Arzneimittelforschung; 1982; 32(3):189-94. PubMed ID: 6896278 [TBL] [Abstract][Full Text] [Related]
19. An antithrombotic agent, NQ301, inhibits thromboxane A2 receptor and synthase activity in rabbit platelets. Jin YR; Cho MR; Lee KS; Lee JJ; Lim Y; Han XH; Oh KW; Hong JT; Yoo HS; Yun YP Basic Clin Pharmacol Toxicol; 2005 Sep; 97(3):162-7. PubMed ID: 16128910 [TBL] [Abstract][Full Text] [Related]
20. Staphylococcal alpha-toxin elicits hypertension in isolated rabbit lungs. Evidence for thromboxane formation and the role of extracellular calcium. Seeger W; Bauer M; Bhakdi S J Clin Invest; 1984 Sep; 74(3):849-58. PubMed ID: 6432850 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]